AP102A - Compounds for use for breaking resistance to antimalarials - Google Patents

Compounds for use for breaking resistance to antimalarials Download PDF

Info

Publication number: AP102A
Authority: AP; ARIPO
Prior art keywords: alkyl; hydrogen; test; antimalarials; parasitemia
Prior art date: 1988-08-06

Application number

APAP/P/1989/000134A

Other languages

English (en)

Other versions

AP8900134A0 (en

Inventor

Gerhard Keilhaver

Horst Koenig

Erich Schlick

Werner Seotz

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-06

Filing date

1989-08-04

Publication date

1990-10-23

1989-08-04 Application filed by Basf Ag filed Critical Basf Ag

1989-10-31 Publication of AP8900134A0 publication Critical patent/AP8900134A0/xx

1990-10-23 Application granted granted Critical

1990-10-23 Publication of AP102A publication Critical patent/AP102A/en

Links

239000003430 antimalarial agent Substances 0.000 title abstract description 13
229940033495 antimalarials Drugs 0.000 title abstract description 10
150000001875 compounds Chemical class 0.000 title description 6
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
239000001257 hydrogen Substances 0.000 claims abstract description 9
125000000217 alkyl group Chemical group 0.000 claims abstract description 6
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
229910052736 halogen Inorganic materials 0.000 claims abstract description 6
150000002367 halogens Chemical class 0.000 claims abstract description 6
125000001424 substituent group Chemical group 0.000 claims abstract description 6
239000002253 acid Substances 0.000 claims abstract description 5
150000007513 acids Chemical class 0.000 claims abstract description 5
150000007962 benzene acetonitriles Chemical class 0.000 claims abstract description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
238000012360 testing method Methods 0.000 claims description 22
230000036772 blood pressure Effects 0.000 claims description 9
150000002431 hydrogen Chemical class 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
230000002213 calciumantagonistic effect Effects 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 abstract description 15
229960003677 chloroquine Drugs 0.000 abstract description 15
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 abstract description 15
239000003814 drug Substances 0.000 abstract description 8
229940079593 drug Drugs 0.000 abstract description 6
201000004792 malaria Diseases 0.000 abstract description 5
XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 abstract description 2
GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 abstract description 2
229960001962 mefloquine Drugs 0.000 abstract description 2
229960005179 primaquine Drugs 0.000 abstract description 2
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 abstract description 2
229960000611 pyrimethamine Drugs 0.000 abstract description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
239000000126 substance Substances 0.000 description 25
208000009182 Parasitemia Diseases 0.000 description 19
208000030852 Parasitic disease Diseases 0.000 description 19
229960001722 verapamil Drugs 0.000 description 14
241000699670 Mus sp. Species 0.000 description 13
230000000694 effects Effects 0.000 description 9
244000045947 parasite Species 0.000 description 8
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000000243 solution Substances 0.000 description 6
238000000034 method Methods 0.000 description 5
238000010998 test method Methods 0.000 description 5
-1 C.. Chemical group 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
241000223830 Plasmodium yoelii Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000011575 calcium Substances 0.000 description 4
230000008602 contraction Effects 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 3
230000000078 anti-malarial effect Effects 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
244000052769 pathogen Species 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000005792 cardiovascular activity Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
125000004417 unsaturated alkyl group Chemical group 0.000 description 2
NVFUSSVYFNPBQF-UHFFFAOYSA-N 2-phenyl-5-(2-phenylethylamino)-2-propan-2-ylpentanenitrile;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C(C)C)(C#N)CCCNCCC1=CC=CC=C1 NVFUSSVYFNPBQF-UHFFFAOYSA-N 0.000 description 1
241001414900 Anopheles stephensi Species 0.000 description 1
206010003671 Atrioventricular Block Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000224453 Mycoplasma coccoides Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000012812 general test Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000036316 preload Effects 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
201000002932 second-degree atrioventricular block Diseases 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

APAP/P/1989/000134A 1988-08-06 1989-08-04 Compounds for use for breaking resistance to antimalarials AP102A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3826796A DE3826796A1 (de)	1988-08-06	1988-08-06	Substituierte phenylacetonitrile zur verwendung als resistenzbrecher

Publications (2)

Publication Number	Publication Date
AP8900134A0 AP8900134A0 (en)	1989-10-31
AP102A true AP102A (en)	1990-10-23

Family

ID=6360386

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1989/000134A AP102A (en)	1988-08-06	1989-08-04	Compounds for use for breaking resistance to antimalarials

Country Status (6)

Country	Link
EP (2)	EP0427747B1 (de)
JP (1)	JPH04500067A (de)
AP (1)	AP102A (de)
AT (1)	ATE113206T1 (de)
DE (2)	DE3826796A1 (de)
WO (2)	WO1990001317A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102016200514B4 (de)	2015-02-04	2019-08-14	Apple Inc.	Verfahren und Vorrichtungen für gesteuerte Wiederherstellung von Fehlerinformationen zwischen unabhängig voneinander betreibbaren Prozessoren

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997044025A1 (en) *	1996-05-23	1997-11-27	G.D. Searle & Co.	Pharmaceutical compositions containing non-racemic verapamil and process for optimizing the pharmaceutical activity of r- and s-verapamil

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA596652A (en) *		1960-04-19	Stuehmer Werner	.alpha.-ISOPROPYL-.alpha.-(.beta.'-DIMETHYLAMINO PROPYL) PHENYL ACETONITRILE, AND A PROCESS OF MAKING SAME
US4593042A (en) *	1985-10-18	1986-06-03	G. D. Searle & Co.	Bicyclo-substituted phenylacetonitrile derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3138488A1 (de) *	1981-09-28	1983-04-14	Knoll Ag, 6700 Ludwigshafen	Verwendung von basisch substituierten phenylacetonritrilen bei der vorbeugenden bekaempfung von krankheiten und mittel dafuer
DE3635931A1 (de) *	1986-10-22	1988-04-28	Basf Ag	Wirkstoffe zur verhuetung von tumormetastasen
US4897403A (en) *	1986-11-18	1990-01-30	The United States Of America As Represented By The Secretary Of The Army	Antimalarial compositions and methods
DE3710806A1 (de) *	1987-03-31	1988-10-27	Basf Ag	Wirkstoff zur tumorbekaempfung

1988
- 1988-08-06 DE DE3826796A patent/DE3826796A1/de not_active Withdrawn
1989
- 1989-08-01 EP EP89908428A patent/EP0427747B1/de not_active Expired - Lifetime
- 1989-08-01 WO PCT/EP1989/000900 patent/WO1990001317A1/de not_active Ceased
- 1989-08-01 JP JP1508341A patent/JPH04500067A/ja active Pending
- 1989-08-01 AT AT89908428T patent/ATE113206T1/de not_active IP Right Cessation
- 1989-08-01 EP EP89908826A patent/EP0427762A1/de not_active Withdrawn
- 1989-08-01 DE DE58908571T patent/DE58908571D1/de not_active Expired - Lifetime
- 1989-08-01 WO PCT/EP1989/000901 patent/WO1990001318A1/de not_active Ceased
- 1989-08-04 AP APAP/P/1989/000134A patent/AP102A/en active

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA596652A (en) *		1960-04-19	Stuehmer Werner	.alpha.-ISOPROPYL-.alpha.-(.beta.'-DIMETHYLAMINO PROPYL) PHENYL ACETONITRILE, AND A PROCESS OF MAKING SAME
US4593042A (en) *	1985-10-18	1986-06-03	G. D. Searle & Co.	Bicyclo-substituted phenylacetonitrile derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102016200514B4 (de)	2015-02-04	2019-08-14	Apple Inc.	Verfahren und Vorrichtungen für gesteuerte Wiederherstellung von Fehlerinformationen zwischen unabhängig voneinander betreibbaren Prozessoren

Also Published As

Publication number	Publication date
AP8900134A0 (en)	1989-10-31
EP0427747A1 (de)	1991-05-22
ATE113206T1 (de)	1994-11-15
DE58908571D1 (de)	1994-12-01
EP0427747B1 (de)	1994-10-26
JPH04500067A (ja)	1992-01-09
WO1990001317A1 (de)	1990-02-22
DE3826796A1 (de)	1990-02-08
WO1990001318A1 (de)	1990-02-22
EP0427762A1 (de)	1991-05-22

Publication	Publication Date	Title
US5849763A (en)	1998-12-15	Use of levobupivacaine as an anesthetic agent
SK279237B6 (sk)	1998-08-05	Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl
JPH01294623A (ja)	1989-11-28	４‐置換イミダゾール誘導体を有効成分とする手術に際して使用する薬剤
EP0370320B1 (de)	1992-09-30	Laktamimide in der Behandlung arzneiresistenter Protozoeninjektionen
Avramov et al.	1998	Effects of nicardipine and labetalol on the acute hemodynamic response to electroconvulsive therapy
JP4885455B2 (ja)	2012-02-29	抗偏頭痛剤として有用なα−アミノアミド誘導体
HU219482B (hu)	2001-04-28	(+)Doxazoszin alkalmazása vizeletfolyást fokozó gyógyászati készítmények előállítására
KR101477043B1 (ko)	2014-12-29	디스키네시아의 치료 또는 예방제
JPWO2002053153A1 (ja)	2004-04-30	神経因性疼痛治療及び予防薬
Winstanley et al.	1987	Currently important antimalarial drugs
JP2012506434A (ja)	2012-03-15	肺動脈高血圧症の治療方法
HU202754B (en)	1991-04-29	Process for producing flavoxate derivatives and pharmaceutical compositions containing them as active components
US10179115B2 (en)	2019-01-15	Methods for treating malaria using potassium channel inhibitors
PL175518B1 (pl)	1999-01-29	Preparat farmaceutyczny do leczenia ostrego bólu drogą blokady czuciowej i sposób wytwarzania preparatu farmaceutycznego
EP0427747B1 (de)	1994-10-26	Substituierte phenylacetonitrile zur verwendung als resistenzbrecher in der malariatherapie
CA1330947C (en)	1994-07-26	Treatment of cardiac arrhythmias
Zargar et al.	2002	Comparative evaluation of the effect of metoprolol and esmolol on rate pressure product and ECG changes during laryngoscopy and endotracheal intubation in controlled hypertensive patients
CA2014166A1 (en)	1991-10-09	Substituted phenylacetonitriles for breaking down resistance
US9446025B2 (en)	2016-09-20	Treatment or prevention of hypotension and shock
EP0717625B1 (de)	2002-06-12	Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
Bhatt et al.	2007	β-Blocking activity of PP-34, a newly synthesized aryloxypropanolamine derivative, and its cardioprotective effect against ischaemia/reperfusion injury in laboratory animals
JP6838676B2 (ja)	2021-03-03	頻脈性不整脈の処置用の医薬組成物
EP3836918B1 (de)	2026-04-08	Task-1-inhibitoren zur verwendung in der behandlung von atrialer arhythmie
AU778129B2 (en)	2004-11-18	A method of treating liver disease and like indications with vasodilating agents
AU7647294A (en)	1995-03-27	A method of treating liver disease and like indications with vasodilating agents

AP102A - Compounds for use for breaking resistance to antimalarials - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (2)

Family

ID=6360386

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (1)

Citations (2)

Family Cites Families (4)

Patent Citations (2)

Cited By (1)

Also Published As

Similar Documents